AstraZeneca Expands AI Partnership with Immunai Through 2027 to Accelerate Oncology Drug Discovery
AstraZeneca has officially announced the expansion of its collaboration with Immunai, a New York-based AI biotechnology company, extending their partnership agreement through 2027. This strategic move underscores the pharmaceutical giant's c<!--autointro-->
Under the terms of the expanded agreement, Immunai is eligible to receive up to $37.5 million across 2026 and 2027. This funding supports the continued utilization of Immunai’s proprietary platform within AstraZeneca’s oncology pipeline.
At the core of this collaboration is Immunai’s flagship platform, AMICA-OS. This advanced system is capable of analyzing clinical immunology data at the single-cell level, providing unprecedented granularity in understanding immune responses.
AstraZeneca will deploy this technology to enhance several critical areas of its oncology programs:
Biomarker Discovery:Identifying novel biological markers for early detection and treatment monitoring.
Patient Stratification: Precisely selecting patient populations most likely to respond to therapy.
Dose Optimization: Determining the most effective and safe dosage levels.
Mechanism-of-Action (MoA) Analysis: Deepening the understanding of how drugs interact with biological targets.
️ A History of Collaboration
This expansion builds upon a robust foundation of cooperation between the two entities:
2024: The initial agreement was established to integrate Immunai’s platform into oncology clinical programs.
2025: The scope of work was widened to include research into inflammatory bowel disease (IBD).
2026-2027: The current expansion focuses on deepening these capabilities to accelerate the delivery of transformative cancer therapies.
Comments & Questions (0)
No comments yet
Be the first to comment!